Merck & Co. Inc (6MK STU) stock market data APIs
€83.564
1.16(1.4%)
as of February 12, 2025
Merck & Co. Inc Financial Data Overview
There is no Profile data available for 6MK.SG.
Prev. Close
82.4
Open
83.564
High
83.558
Low
82.376
52 wk Range
82.4-122.6468
Market Cap
162 424 M
Dividends (Yield)
0.0235
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-04
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
Merck & Co., Inc. (MRK): A Bull Case Theory
We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)'s share was trading at ...
Why Merck & Co., Inc. (MRK) is Declining
We recently published an article titled Why These 10 Dividend Stocks Are Declining? In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend...
Jim Cramer on Merck & Co., Inc. (MRK): ‘Drug Stocks Are Really Getting Hurt’
We recently published an article titled Jim Cramer Discusses These 10 Stocks & An Outfit Better Than DeepSeek.In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands ...
Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
Approval is based on the Phase 3 KEYNOTE-671 Trial KIRKLAND, QC, Feb. 11, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Health Canada has grant...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
